Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye.
Unlike traditional anti-angiogenic drugs that prevent new vessel formation, OXiGENE’s VDAs targeted existing immature blood vessels within tumors. These agents compromise the tumor's core vasculature, leading to extensive necrosis (cell death) within the center of the tumor. Oxigene
Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503 Investigated as a topical or systemic treatment to
OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer Anaplastic Thyroid Cancer